Filter by year
June 10, 2026
Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing authorisation in Europe from the European Commission Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if approved by Health Canada) MONTREAL, June 10, 2026 – ExCellThera Inc. (“ExCellThera”), a global leader in blood stem cell […]
Read moreMarch 10, 2026
– Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes – Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid, Spain MONTREAL, March 10, 2026 – ExCellThera Inc. (ExCellThera), a world leader […]
Read moreFebruary 16, 2026
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, February 16, 2026 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, has […]
Read more